KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed EBT for 15 consecutive years, with $86.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT rose 144.47% year-over-year to $86.3 million, compared with a TTM value of $323.2 million through Dec 2025, up 185.63%, and an annual FY2025 reading of $323.2 million, up 185.63% over the prior year.
  • EBT was $86.3 million for Q4 2025 at Alnylam Pharmaceuticals, down from $280.6 million in the prior quarter.
  • Across five years, EBT topped out at $280.6 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
  • Average EBT over 5 years is -$123.3 million, with a median of -$180.3 million recorded in 2021.
  • Peak annual rise in EBT hit 358.2% in 2025, while the deepest fall reached 269.92% in 2025.
  • Year by year, EBT stood at -$260.3 million in 2021, then increased by 20.47% to -$207.0 million in 2022, then surged by 33.49% to -$137.7 million in 2023, then tumbled by 40.87% to -$194.0 million in 2024, then soared by 144.47% to $86.3 million in 2025.
  • Business Quant data shows EBT for ALNY at $86.3 million in Q4 2025, $280.6 million in Q3 2025, and -$41.3 million in Q2 2025.